TCR Library Program
Various Solid Tumors
DiscoveryActive
Key Facts
About Medigene
Medigene is a clinical-stage biotech focused on engineering T-cell receptor (TCR)-modified T-cell therapies for solid tumors, a notoriously difficult-to-treat area. Its strategy is built on two proprietary technology pillars: a high-throughput TCR discovery platform and a PD1-41BB costimulatory switch receptor designed to enhance T-cell persistence and function. The company has advanced its lead candidate, MDG1011, into Phase I/II clinical trials and is actively building a pipeline of novel TCRs through internal discovery and partnerships. As a publicly traded entity, Medigene aims to validate its platform and establish a leadership position in the evolving TCR-T cell therapy landscape.
View full company profileTherapeutic Areas
Other Various Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| NUC-8232 | NuCana | Phase 1 |
| Solid Tumor Profiling | Diatech Pharmacogenetics | Commercial |
| BAVENCIO (avelumab) | EMD Serono | Approved |
| Jemperli (dostarlimab) combinations | GSK | Phase 3 |
| FoundationOne®CDx Indication Expansion | Foundation Medicine | Approved/Commercial |
| FoundationOne®Liquid CDx Indication Expansion | Foundation Medicine | Approved/Commercial |
| Taiho Oncology Pipeline | Otsuka Holdings | Multiple (I-III) |
| Lenvatinib + Pembrolizumab | Eisai | Phase 3 / Marketed |
| PD-1/PD-L1 Inhibitor | PeptiDream | Phase 1 |
| Cadonilimab (AK104) | Akeso | Phase III |
| TEVIMBRA (tislelizumab) | BeOne Medicines | Approved / Phase 3 |
| Early I-O Pipeline | Ipsen | Pre-clinical / Phase 1 |